Subscribe
Share
Share
Embed
Reflux is a failure of the barrier between stomach and esophagus before it is a problem of acid, and the episode follows two patients through that idea. A man with grade C erosive esophagitis and a hiatal hernia shows what the Los Angeles grade decides, why transient sphincter relaxations, the hernia, lying flat, and obesity cause reflux, and why H2 blockers fade. It then covers PPI timing and speed, vonoprazan, maintenance, and the safety of long-term PPI use. A woman with non-erosive reflux shows how to step down and confirm the diagnosis. The episode closes with board traps.
Topics covered
Key decisions
This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.
For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.
Questions or feedback: hello@boardpearls.com.
The most complete gastroenterology board-review podcast on the web, and it is entirely free. This is the GI series from Board Pearls: board review built around clinical reasoning, not recall. Every episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards. No trivia, no textbook dictation, just the thinking that earns the point.
Over 100 episodes span the full blueprint across nine modules (esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics), grouped by chapter and built from the guidelines and pivotal trials the boards are written from: ACG, AGA, AASLD, and ASGE.
Pair it with the written curriculum, question bank, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode one of three of the GERD and Refractory Reflux chapter, in the Esophageal Disorders module. This episode is reflux with erosive esophagitis, through two patients. A fifty-two-year-old man with nightly heartburn and a hiatal hernia is followed from his first endoscopy. His case teaches what the grade of esophagitis decides, why he refluxes when his stomach makes a normal amount of acid and how that shapes the measures beyond drugs, why his over-the-counter drug stopped working, why the timing of a proton pump inhibitor, PPI, decides whether it works at all, when vonoprazan is the better choice, how long he stays on treatment, and what to tell him about years on a PPI. A thirty-three-year-old woman with heartburn and a normal endoscopy teaches how non-erosive reflux is confirmed and why it's managed with less.
Here's the first patient. A fifty-two-year-old man has had heartburn most nights for three years, worse after big dinners and when he lies down. He tastes acid in his throat when he bends over. He's gained thirty pounds over the past decade. Antacids and over-the-counter famotidine helped at first, then stopped helping. Because he's a man over fifty with years of reflux and central obesity, all risk factors for Barrett esophagus, he has an upper endoscopy. It shows a four-centimeter sliding hiatal hernia, and mucosal breaks that run together across the tops of two folds, covering about a third of the circumference.
He has gastroesophageal reflux disease, GERD, with erosive esophagitis, Los Angeles grade C, and a sliding hiatal hernia. The Los Angeles classification grades mucosal breaks by length and circumferential extent, and each grade has its own next step, so the grade is the first thing to read in any reflux endoscopy.
Grade A is one or more breaks no longer than five millimeters that don't bridge the tops of two folds. It overlaps with what's seen in healthy people, so the Lyon consensus treats it as supportive rather than definitive evidence of reflux disease, and grade A with an acid exposure time of four to six percent is read as borderline. Grade B is breaks longer than five millimeters that still don't bridge folds, and that counts as objective evidence of reflux, though it was historically treated more cautiously than the higher grades. Grade C is breaks running continuously between the tops of two or more folds, involving less than seventy-five percent of the circumference. Grade D involves more than seventy-five percent, and it's the strongest predictor of Barrett esophagus at follow-up.
His grade C settles three things, each for its own reason. He has objective reflux disease, so he doesn't need reflux monitoring to prove it. His disease is severe enough to need twice-daily acid suppression to heal. And he needs a repeat endoscopy after healing, because inflammation this severe can hide Barrett esophagus underneath it. The same three things are true for grade D. His hernia is measured from the diaphragmatic pinch to the top of the gastric folds, and its size is always reported, because it decides which antireflux procedure is possible later.
Before choosing his drug, it helps to know why he refluxes, because the reasons are also the measures beyond drugs. Reflux is a failure of the barrier before it's a problem of acid. Most people with reflux make normal amounts of acid; what's gone wrong is the barrier between the stomach and the esophagus. That barrier is the lower esophageal sphincter and the crural diaphragm working in series, supported by the angle of His and the segment of esophagus that sits in the abdomen. The sphincter is a two- to four-centimeter zone of smooth muscle that stays contracted at rest, ten to thirty-five millimeters of mercury above gastric pressure. The crural diaphragm is striated muscle that wraps the esophagus where it passes through the hiatus and pinches it shut with every breath, cough, and strain, at exactly the moments when pressure pushes stomach contents upward. Manometry records both together, so the sphincter pressure on a report is really the pressure of the whole junction.
Most patients with reflux have a normal resting sphincter pressure, which is the first hint that the failure is dynamic. Severe esophagitis often shows a sphincter under ten millimeters of mercury, but in most patients reflux happens during transient lower esophageal sphincter relaxations: sudden, prolonged openings lasting more than ten seconds, not triggered by a swallow and not followed by a peristaltic wave. They're part of the belch reflex. Stretching of the gastric fundus by a meal or gas signals through the vagus nerve to the nucleus tractus solitarius, which relaxes the sphincter, inhibits the crura, and shortens the esophagus to vent gas. Cholecystokinin one receptors in the sphincter muscle mediate the relaxation, and gamma-aminobutyric acid type B, GABA-B, receptors on inhibitory neurons brake the reflex, which is why the GABA-B agonist baclofen suppresses them. Healthy people have two to six an hour. In reflux disease the number isn't higher; more of them carry acid instead of gas. They account for about seventy percent of reflux episodes, even in severe disease.
His hernia makes it worse in several ways. A sliding hernia pulls the junction up into the chest and separates the sphincter from the diaphragm, and the sphincter alone can't hold against the pressure gradient during deep breaths, coughing, or straining. Crural contraction then creates a pouch of stomach above the diaphragm whose contents are ready to reflux. Large hernias also bring more transient relaxations with gastric distention. The angle of His and the flap valve it creates are lost. And material that empties into the hernia sac can come straight back up during the sphincter relaxations of normal swallowing. So a hernia turns marginal barrier function into disease.
The timing of his symptoms has a cause too, and it explains two of his instructions. After a meal, food buffers most of the stomach's acid, but a layer of unbuffered acid floats on top of the food in the cardia, right below the squamocolumnar junction: the acid pocket. When a transient relaxation happens after dinner, the acid pocket refluxes first, because it's closest to the sphincter, and his hernia moves it even closer. That pocket is also what an alginate targets, by forming a raft that displaces it away from the junction. At night, lying flat removes gravity, and he swallows and makes saliva less, so acid that refluxes sits longer. That's why nighttime reflux does disproportionate damage, and why he's told to raise the head of his bed and stop eating late heavy dinners.
Clearance matters by day too. Gravity and peristalsis clear refluxed acid in seconds, and swallowed alkaline saliva, with some bicarbonate from the esophageal submucosal glands, neutralizes what's left. So Sjogren syndrome or head and neck radiation, by cutting saliva, can turn a normal acid burden into refractory symptoms. Ineffective esophageal motility, defined by weak or failed swallows on at least seventy percent of swallows, or at least fifty percent under a looser cutoff, prolongs acid contact and is overrepresented in erosive disease.
His weight adds to all of it, and it's the third instruction. Abdominal fat raises intra-abdominal pressure and the pressure gradient that pushes stomach contents upward at every relaxation, and obesity brings more hernias and more relaxations with gastric distention. Visceral fat also releases cytokines that weaken the esophageal barrier by widening the spaces between cells. Central obesity is also the strongest modifiable risk factor for Barrett esophagus and adenocarcinoma, so weight loss belongs on his reflux treatment list, not only on his metabolic one. If an obese patient with reflux goes to bariatric surgery, the operation is Roux-en-Y gastric bypass, because a sleeve gastrectomy worsens reflux.
Choosing his drug starts with where each one acts. The parietal cell makes acid with the hydrogen-potassium ATPase, the proton pump, on its canalicular membrane. Three signals switch it on: gastrin through the cholecystokinin two receptor, histamine through the H2 receptor, and acetylcholine through the M3 receptor. All three converge on that one pump, which is why blocking the pump works better than blocking any single signal.
That explains his famotidine. An H2 blocker, such as famotidine, cimetidine, or nizatidine, blocks only the histamine signal; ranitidine was withdrawn for nitrosamine contamination. H2 blockers relieve mild symptoms in roughly half to two thirds of people, but within days the cell adapts by leaning on the other two signals, so the effect fades, and they heal erosive esophagitis poorly. His famotidine didn't stop working because his disease changed; it stopped working because of tachyphylaxis. So erosive esophagitis isn't treated with an H2 blocker. Its place is mild intermittent symptoms, and famotidine is the one preferred while breastfeeding, because it has the lowest excretion into breast milk.
A proton pump inhibitor binds the pump itself, covalently and irreversibly, but it has two catches, and both decide how he takes it. The first is timing. A PPI is a prodrug, activated only by acid in the canaliculus of an actively secreting parietal cell, and that happens with meals. Its half-life in the blood is only about ninety minutes. So the drug has to be in his blood when the pumps switch on: thirty to sixty minutes before breakfast, and thirty to sixty minutes before dinner when it's twice daily. Taken with breakfast instead of before it, a PPI loses about thirty percent of its efficacy, and taken at bedtime it misses most of its target. Dexlansoprazole, with a modified release in two phases, one in the proximal and one in the distal small bowel, is the partial exception that doesn't need meal timing.
The second catch is speed. The cell keeps making new pumps that must each be inactivated, so a PPI takes three to five days to reach steady-state inhibition, which is why it's useless for on-demand relief of an acute symptom. PPIs are cleared mainly by the liver enzyme cytochrome P450 two C nineteen, CYP2C19, and people vary widely in how fast they clear them, so rapid metabolizers may need a higher dose or twice-daily dosing for the same effect.
The PPIs also differ in strength. Measured against omeprazole twenty milligrams as one, pantoprazole twenty is about a quarter, lansoprazole fifteen about nine tenths, esomeprazole twenty about one point six, and rabeprazole twenty about one point eight. Pantoprazole is the weakest standard-dose PPI, and rabeprazole is the most potent. Rabeprazole and esomeprazole are also less affected by CYP2C19 variation, which makes them useful when a rapid metabolizer is suspected.
So he starts a standard-dose PPI, such as omeprazole twenty milligrams, twice daily, before breakfast and before dinner, for eight to twelve weeks, along with bed elevation, earlier lighter dinners, and weight loss. Dosing starts low and steps up in most patients: a once-daily PPI before breakfast heals eighty to ninety-five percent of erosive esophagitis and controls symptoms in most non-erosive disease over eight to twelve weeks. Twice-daily dosing is kept for grade C or D at presentation, as in him, for a peptic stricture, for Barrett esophagus, and when once daily doesn't control symptoms. Seventy to eighty percent of patients on twice-daily PPI have nocturnal acid breakthrough, a gastric pH below four for more than an hour at night. A bedtime H2 blocker can cover it short term, though its relevance and durability are debated, because tachyphylaxis limits it.
Vonoprazan is the alternative for him, and its differences explain when it's preferred. It's a potassium-competitive acid blocker, the only one approved in the United States, and a separate class. It binds the pump ionically rather than covalently, but it binds active and inactive pumps alike, it isn't a prodrug, it's stable in acid without an enteric coat, and its half-life is seven to nine hours. So it suppresses acid faster, more completely, and around the clock, without any meal timing. It's cleared mainly by a different enzyme, cytochrome P450 three A four, CYP3A4, so CYP2C19 variation doesn't matter. It's more potent than any approved PPI dose: ten milligrams approximates omeprazole sixty milligrams once daily, and twenty approximates omeprazole sixty twice daily.
The evidence for vonoprazan in erosive esophagitis comes from a randomized trial of about a thousand patients, comparing vonoprazan twenty milligrams with lansoprazole thirty milligrams for eight weeks of healing, then vonoprazan ten or twenty milligrams against lansoprazole fifteen for twenty-four weeks of maintenance. Vonoprazan was noninferior and then superior for both healing and maintenance, healing about ninety-three percent overall, and its advantage was largest in grades C and D, where more patients were healed by the second week. It's also part of newer Helicobacter pylori regimens, where stronger acid suppression helps the antibiotics work. It's avoided while breastfeeding, because there are no lactation data. So for him, vonoprazan twenty milligrams daily for eight weeks of healing, then ten or twenty milligrams daily for maintenance, is a reasonable first choice too, and it's the step to take if a correctly timed PPI doesn't heal him.
His follow-up endoscopy after twelve weeks shows healed mucosa and no Barrett esophagus.
How long he stays on treatment follows from his grade. After severe erosive disease, esophagitis comes back within weeks of stopping, so he needs maintenance therapy, generally at the dose that healed him.
The second patient shows why the most common form of reflux is managed with less. A thirty-three-year-old woman has heartburn and regurgitation, and her endoscopy is normal: non-erosive reflux disease, the majority of reflux seen in practice. Once her symptoms are controlled, she can step down to the lowest dose that works, use the drug on demand, or try a drug holiday, because her disease doesn't need the pump suppressed around the clock. The same de-escalation suits mild erosive disease. Because her endoscopy is normal, there's no endoscopic proof of reflux, so if she doesn't respond to a PPI, her diagnosis is unproven, and the next step is reflux monitoring off PPI to establish it. And non-erosive disease doesn't call for Barrett screening beyond the standard age and risk-factor criteria.
Committing him to years of treatment raises the question he asks: is it safe to take a PPI for years? The list of reported associations is long: vitamin B12 deficiency, from less acid to release food-bound B12, low magnesium, iron deficiency, calcium absorption changes with conflicting fracture data, Clostridioides difficile infection, community-acquired pneumonia, interstitial nephritis, chronic kidney disease, microscopic colitis, food allergy, eosinophilic esophagitis, dementia, cardiovascular events, and death from any cause. Almost all of it comes from observational studies, which can't separate the drug from the illnesses of the people who take it.
The randomized evidence is reassuring. A trial of nearly eighteen thousand patients on rivaroxaban or aspirin, randomized to pantoprazole forty milligrams daily or placebo for three years, found no difference in any of those outcomes except a small increase in enteric infections. That suggests most of the observational associations were residual confounding, and the dementia and kidney signals in particular haven't held up. So he's told to use the lowest dose and shortest duration that control his disease, without blanket discontinuation. And a PPI should never be stopped in a patient with severe erosive esophagitis, a peptic stricture, or Barrett esophagus. He has the first, so his PPI stays.
Two related questions come up often in patients like him. If he were on clopidogrel, the concern is that clopidogrel is a prodrug activated by CYP2C19, the same enzyme that clears PPIs, so omeprazole and esomeprazole in particular reduce its activation in laboratory studies. Clinical trials haven't shown a meaningful increase in cardiovascular events, so the PPI isn't avoided; pantoprazole or rabeprazole can be chosen if there's concern, because they interact less with that enzyme. And Helicobacter pylori: reflux disease is neither a reason to test for it nor a reason not to treat it if it's found. Eradication in a patient with a duodenal ulcer can occasionally unmask reflux esophagitis, and gastritis of the gastric body that lowers acid output may protect against Barrett esophagus and adenocarcinoma, but routine testing in reflux hasn't been shown to change outcomes.
Here are the traps the boards set in these patients.
At endoscopy, calling grade A esophagitis proof of reflux overreads a finding seen in healthy people. Ordering a pH study when grade B or worse already proves reflux adds nothing. And skipping the repeat endoscopy after grade C or D heals misses the Barrett that inflammation was hiding.
In mechanism, assuming a reflux patient must have a weak sphincter misses the point that most have a normal resting pressure and reflux through transient relaxations.
In drug choice, treating erosive esophagitis with an H2 blocker fails because of tachyphylaxis. Taking a PPI at bedtime or with food leaves the patient functionally untreated. And using a PPI on demand for acute symptoms ignores the three to five days it takes to work.
In long-term care, stopping maintenance in severe erosive disease out of fear of side effects brings the esophagitis back within weeks. Keeping a patient with non-erosive disease on full-dose suppression indefinitely ignores de-escalation. And avoiding a PPI in a patient on clopidogrel isn't supported by clinical outcomes.
So, start to finish.
Grade the esophagitis first: grade B or worse is objective reflux, and grades C and D need twice-daily acid suppression and a repeat endoscopy after healing to look for Barrett. Report the hernia size.
Reflux is a barrier failure. Transient sphincter relaxations carry the post-meal acid pocket upward, a hiatal hernia separates the sphincter from the diaphragm, lying flat removes clearance, and obesity raises the pressure, which is why bed elevation, earlier dinners, and weight loss belong in treatment.
H2 blockers fade within days and don't heal erosive disease. PPIs are prodrugs that bind active pumps, so they're taken thirty to sixty minutes before meals and take days to work. Vonoprazan works around the clock without meal timing and is strongest in severe grades.
Severe erosive disease needs maintenance; non-erosive and mild disease can step down. And the long-term risks are much smaller than the observational studies suggested, so a PPI is never stopped in severe esophagitis, stricture, or Barrett.
Episode two is the patient whose symptoms continue despite a PPI, the order of steps that finds out whether she has reflux at all, and who should have antireflux surgery.